Dysgeusia, Taste, Altered
Conditions
Brief summary
Purpose and Objective: Compare the incidence of taste alteration in treatment vs. control arms and Compare weight loss in treatment vs. control arms
Detailed description
After patients is explained all potential risks and study guidelines all patients will be given an ICF to sign if they wish to participate. Once the ICF has been signed by patient approximately between 3-5 days will undergo a screening to determine protocol eligibility. If patients qualifies (eligible) for study patients will be randomly assigned either to the miracle fruit intervention or to supportive measures at first and later participants will cross over to the other intervention
Interventions
DRUGMiracle Fruit
one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
Sponsors
Mt. Sinai Medical Center, Miami
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients will be randomly assigned either to the miracle fruit intervention or to supportive measures at first and later participants will cross over to the other intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The inclusion criteria are the following: * Patients over 18 years old with a life expectancy of 3 months or more. * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * At enrollment, patients must be able to take oral medications and food reliably without any risk factors for aspiration. * Patients that have received at least 1 cycle of chemotherapy and have at least 1 more cycle planned. * Patients receiving the following drug-containing chemotherapy regimens: cyclophosphamide, carboplatin, cisplatinum, gemcitibine, methotrexate, doxorubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, oxaliplatin, irinotecan and etoposide. * Patients receiving radiotherapy at the time of chemotherapy are allowed, with the exception of patients receiving radiotherapy for head and neck tumors * Patients with the ability to understand and the willingness to sign a written informed consent document written in English and answer all appropriate questionnaires in English or Spanish. (see Appendix 3) * Patients with brain metastases are eligible if neurologically stable after appropriate treatment (surgery and/or radiation).
Exclusion criteria
* • Patient that have mechanical obstruction of the alimentary tract. * Patients who have developed decreased/altered taste sensation for any reason besides chemotherapy * Patients with malabsorption or intractable vomiting. * Patients who have extensive dental caries * Patients who have poor oral hygiene * Patients receiving radiotherapy for head and neck tumors. * Previous surgery that included ablation or removal of the olfactory component of the taste. * Untreatable oral thrush. * Women that are pregnant, nursing or of childbearing potential and unwilling to use contraception, as the effects of the miracle fruit on the developing human fetus are unknown. * Patients with an ANC \< 500/uL . * Patients with poorly controlled diabetes mellitus (DM) as determined by their primary physicians will be excluded from the study. All DM patients will be required to check their blood sugar on their usual home glucose meters at least once a day, prior to the ingestion of the miracle fruit. If the patient does not a glucose meter, we will provide the patient with one. Any case of hypoglycemia (blood sugar below 60) should be reported immediately to the treatment physician and the patient should stop the miracle fruit treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the incidence of taste alteration in treatment vs. control arms | 12 months | Taste alteration will be assessed using questions from the Wickham questionnaire of taste alterations. Patient responses to these questions will be transformed to a 0 to 100 scale. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare weight loss in treatment vs. control arms | 12 months | Weight loss will be determined by comparing baseline (pre-intervention) weight with on-study weight. |
Outcome results
None listed